QLT Ophthalmics, Inc. (QOI), a wholly-owned U.S. subsidiary of QLT Inc. (NASDAQ: QLTI; TSX: QLT), selected Veeva System's multi-tenant SaaS CRM system built on the cloud computing model. QOI was formed by QLT Inc. in Q4 2009 to take over the sales and marketing of Visudyne® in the U.S. from Novartis Pharma AG ("Novartis"). Veeva CRM™ proved the only system flexible and scalable enough to meet QOI's rapidly growing needs, according to QOI's Director of Commercial Operations, Scott Jones.
“We looked at most of the Pharma CRM vendors, but knew fairly quickly that Veeva was the best fit for us. The fact that they were able to implement the system in less than 6 weeks was the final feather in their cap”
"Veeva CRM is easily scalable, which was very important to us as we hope to scale-up our commercial operations as we bring new therapeutics to the market," said Jones. "Plus, the Veeva CRM system is as flexible in its pricing model as it is technologically. We didn't have to make a huge investment in Veeva up-front but when we are ready for more 'system' with additional functionality and seat licenses, we can pay incrementally to build on and not have wasted any money with our initial outlay."
The ophthalmic pharmaceutical company went live with the complete Veeva CRM suite in February. A multi-tenant SaaS application built on the cloud computing model, Veeva CRM requires no hardware or software to purchase, scale, or maintain. Plus, customers benefit from free, automatic upgrades every 90 days so users will always be working on the latest version of the software with the very latest compliance changes and system enhancements- all very appealing to small companies like QOI.
"We looked at most of the Pharma CRM vendors, but knew fairly quickly that Veeva was the best fit for us. The fact that they were able to implement the system in less than 6 weeks was the final feather in their cap," concluded Jones.
Exploring instruments for assay development and optimization